Publications

Sahr K, Dias DCampos, Sanchez R, Chen D, Chen SW, Gudas LJ, Baron MH.  2002.  Structure, upstream promoter region, and functional domains of a mouse and human Mix paired-like homeobox gene.. Gene. 291(1-2):135-47.

Mohn D, Chen SW, Dias DCampos, Weinstein DC, Dyer MA, Sahr K, Ducker CE, Zahradka E, Keller G, Zaret KS et al..  2003.  Mouse Mix gene is activated early during differentiation of ES and F9 stem cells and induces endoderm in frog embryos.. Dev Dyn. 226(3):446-59.

Mohn D, Chen SW, Dias DCampos, Weinstein DC, Dyer MA, Sahr K, Ducker CE, Zahradka E, Keller G, Zaret KS et al..  2003.  Mouse Mix gene is activated early during differentiation of ES and F9 stem cells and induces endoderm in frog embryos.. Dev Dyn. 226(3):446-59.

Mohn D, Chen SW, Dias DCampos, Weinstein DC, Dyer MA, Sahr K, Ducker CE, Zahradka E, Keller G, Zaret KS et al..  2003.  Mouse Mix gene is activated early during differentiation of ES and F9 stem cells and induces endoderm in frog embryos.. Dev Dyn. 226(3):446-59.

Lane MA, Xu J, Wilen EW, Sylvester R, Derguini F, Gudas LJ.  2008.  LIF removal increases CRABPI and CRABPII transcripts in embryonic stem cells cultured in retinol or 4-oxoretinol.. Mol Cell Endocrinol. 280(1-2):63-74.

Liu L, Derguini F, Gudas LJ.  2009.  Metabolism and regulation of gene expression by 4-oxoretinol versus all-trans retinoic acid in normal human mammary epithelial cells.. J Cell Physiol. 220(3):771-9.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM.  2010.  Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.. Cancer Biol Ther. 9(9):678-84.

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP.  2013.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.. Oncol Rep. 30(1):131-8.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.. Anticancer Res. 33(12):5235-42.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.. Anticancer Res. 33(6):2381-90.

Simandi Z, Horvath A, Wright LC, Cuaranta-Monroy I, De Luca I, Karolyi K, Sauer S, Deleuze J-F, Gudas LJ, Cowley SM et al..  2016.  OCT4 Acts as an Integrator of Pluripotency and Signal-Induced Differentiation.. Mol Cell. 63(4):647-661.

Simandi Z, Horvath A, Wright LC, Cuaranta-Monroy I, De Luca I, Karolyi K, Sauer S, Deleuze J-F, Gudas LJ, Cowley SM et al..  2016.  OCT4 Acts as an Integrator of Pluripotency and Signal-Induced Differentiation.. Mol Cell. 63(4):647-661.

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.

Molina AM, van der Mijn JC, Christos P, Wright J, Thomas C, Dutcher JP, Nanus DM, Tagawa ST, Gudas LJ.  2020.  NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.. Invest New Drugs.

Williams RM, Shah J, Mercer E, Tian HS, Thompson V, Cheung JM, Dorso M, Kubala JM, Gudas LJ, de Stanchina E et al..  2021.  Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.. Front Pharmacol. 12:790913.

Williams RM, Shah J, Mercer E, Tian HS, Thompson V, Cheung JM, Dorso M, Kubala JM, Gudas LJ, de Stanchina E et al..  2021.  Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.. Front Pharmacol. 12:790913.

Laursen KB, Chen Q, Khani F, Attarwala N, Gross SS, Dow L, Nanus DM, Gudas LJ.  2021.  Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma.. Front Oncol. 11:783856.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, Robinson BD, Khani F, Alsaleem M, Ntekim A et al..  2022.  The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer.. Cancers (Basel). 14(20)

Del Aguila EMere, Tang X-H, Gudas LJ.  2022.  Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A.. Oncol Res Treat.

van der Mijn JC, Chen Q, Laursen KB, Khani F, Wang X, Dorsaint P, Sboner A, Gross SS, Nanus DM, Gudas LJ.  2022.  Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).. Mol Carcinog.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, Chen Q, Gross SS, Nanus DM, Gudas LJ.  2023.  Novel genetically engineered mouse models for clear cell renal cell carcinoma.. Sci Rep. 13(1):8246.

DiKun KM, Gudas LJ.  2023.  Vitamin A and retinoid signaling in the kidneys.. Pharmacol Ther. 248:108481.

Patke R, Harris AE, Woodcock CL, Thompson R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson BD et al..  2024.  Epitranscriptomic mechanisms of androgen signalling and prostate cancer.. Neoplasia. 56:101032.